References
- Parry HM, Bruton R, Stephens C, Brown K, Amirthalingam G, Hallis B, Otter A, Zuo J, Moss P. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people. MedRxiv [prepr]. 2021. doi:10.1101/2021.05.15.21257017.
- Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021. doi:10.1056/NEJMc2104974.
- Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC, Lee SA, Roan NR. mRNA vaccine-induced SARS-CoV-2-specific T cells recognize B.1.1.7 and B.1.351 variants but differ in longevity and homing properties depending on prior infection status. BioRxiv [prepr]. 2021. doi:10.1101/2021.05.12.443888.
- Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, Flowers MW, Hussaini L, Ciric CR, Bechnack S, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. BioRxiv [prepr]. 2021. doi:10.1101/2021.05.09.443299.
- Bernal JL, Andrews N, Gower C, Stowe J, Tessier E, Simmons R, Ramsay M. Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. KnowledgeHub [prepr]. 2021; [accessed May 20]. https://khub.net/documents/135939561/430986542/Effectiveness+of+BNT162b2+mRNA+vaccine+and+ChAdOx1+adenovirus+vector+vaccine+on+mortality+following+COVID-19.pdf/9884d371-8cc8-913c-211c-c2d7ce4dd1c3.
- Fairman J, Agarwal P, Barbanel S, Behrens C, Berges A, Burky J, Davey P, Fernsten P, Grainger C, Guo S, et al. Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23). Vaccine. 2021;S0264-410X:00374–1.
- Wang X, Li B, Kim YJ, Wang YC, Li Z, Yu J, Zeng S, Ma X, Choi IY, Di Biase S, et al. Targeting monoamine oxidase A for T cell-based cancer immunotherapy. Sci Immunol. 2021;6(59):eabh2383. doi:10.1126/sciimmunol.abh2383.